Skip to main content
. 2018 Aug 20;58(3):375–387. doi: 10.1007/s40262-018-0704-z

Fig. 1.

Fig. 1

Goodness-of-fit plots for the final population-pharmacokinetic model of risankizumab. a Population-predicted vs. observed risankizumab plasma concentrations; b individual-predicted vs. observed risankizumab plasma concentrations; c conditional weighted residuals vs. population-predicted concentrations; and d conditional weighted residuals vs. time after first dose